Tom Dorsett has 27 years of experience as a healthcare entrepreneur and business development executive. He founded and exited two successful companies, NuScribe and ePatientFinder, and co-founded RazorMetrics in 2018 to lower drug spend for self-funded employers and health plans.
Polypharmacy is a cost and safety problem that is solvable. The right technology platform can reduce it by identifying risky regimens, route specific “stop/switch/consolidate” opportunities to clinicians, and track whether changes stick through refill and adherence patterns.
Multiple studies have shown no correlation between R&D costs and the launch price of new drugs though that is an argument often used by drugmakers to prevent a cap on pricing. Still, one way to keep costs low, is for organizations to leverage health technology like AI and improve formulary compliance.
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
Every health plan is required to use real-time benefit tools, which allow physicians to access drug pricing and a patient’s benefit information at the point of care. But, to date, RTBTs haven’t delivered on the promised savings.
Minorities—along with the elderly and women—have historically been underrepresented in clinical trials.